2023-03-012024-02-292024-02-29false06828498TOTALLY PHARMACY LTD2024-11-28iso4217:GBPxbrli:pure068284982023-03-01068284982024-02-29068284982023-03-012024-02-29068284982022-03-01068284982023-02-28068284982022-03-012023-02-2806828498bus:SmallEntities2023-03-012024-02-2906828498bus:AuditExempt-NoAccountantsReport2023-03-012024-02-2906828498bus:FullAccounts2023-03-012024-02-2906828498bus:PrivateLimitedCompanyLtd2023-03-012024-02-2906828498core:WithinOneYear2024-02-2906828498core:AfterOneYear2024-02-2906828498core:WithinOneYear2023-02-2806828498core:AfterOneYear2023-02-2806828498core:ShareCapital2024-02-2906828498core:SharePremium2024-02-2906828498core:RevaluationReserve2024-02-2906828498core:OtherReservesSubtotal2024-02-2906828498core:RetainedEarningsAccumulatedLosses2024-02-2906828498core:ShareCapital2023-02-2806828498core:SharePremium2023-02-2806828498core:RevaluationReserve2023-02-2806828498core:OtherReservesSubtotal2023-02-2806828498core:RetainedEarningsAccumulatedLosses2023-02-2806828498core:LandBuildings2024-02-2906828498core:PlantMachinery2024-02-2906828498core:Vehicles2024-02-2906828498core:FurnitureFittings2024-02-2906828498core:OfficeEquipment2024-02-2906828498core:NetGoodwill2024-02-2906828498core:IntangibleAssetsOtherThanGoodwill2024-02-2906828498core:ListedExchangeTraded2024-02-2906828498core:UnlistedNon-exchangeTraded2024-02-2906828498core:LandBuildings2023-02-2806828498core:PlantMachinery2023-02-2806828498core:Vehicles2023-02-2806828498core:FurnitureFittings2023-02-2806828498core:OfficeEquipment2023-02-2806828498core:NetGoodwill2023-02-2806828498core:IntangibleAssetsOtherThanGoodwill2023-02-2806828498core:ListedExchangeTraded2023-02-2806828498core:UnlistedNon-exchangeTraded2023-02-2806828498core:LandBuildings2023-03-012024-02-2906828498core:PlantMachinery2023-03-012024-02-2906828498core:Vehicles2023-03-012024-02-2906828498core:FurnitureFittings2023-03-012024-02-2906828498core:OfficeEquipment2023-03-012024-02-2906828498core:NetGoodwill2023-03-012024-02-2906828498core:IntangibleAssetsOtherThanGoodwill2023-03-012024-02-2906828498core:ListedExchangeTraded2023-03-012024-02-2906828498core:UnlistedNon-exchangeTraded2023-03-012024-02-2906828498core:MoreThanFiveYears2023-03-012024-02-2906828498core:Non-currentFinancialInstruments2024-02-2906828498core:Non-currentFinancialInstruments2023-02-2806828498dpl:CostSales2023-03-012024-02-2906828498dpl:DistributionCosts2023-03-012024-02-2906828498core:LandBuildings2023-03-012024-02-2906828498core:PlantMachinery2023-03-012024-02-2906828498core:Vehicles2023-03-012024-02-2906828498core:FurnitureFittings2023-03-012024-02-2906828498core:OfficeEquipment2023-03-012024-02-2906828498dpl:AdministrativeExpenses2023-03-012024-02-2906828498core:NetGoodwill2023-03-012024-02-2906828498core:IntangibleAssetsOtherThanGoodwill2023-03-012024-02-2906828498dpl:GroupUndertakings2023-03-012024-02-2906828498dpl:ParticipatingInterests2023-03-012024-02-2906828498dpl:GroupUndertakingscore:ListedExchangeTraded2023-03-012024-02-2906828498core:ListedExchangeTraded2023-03-012024-02-2906828498dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-03-012024-02-2906828498core:UnlistedNon-exchangeTraded2023-03-012024-02-2906828498dpl:CostSales2022-03-012023-02-2806828498dpl:DistributionCosts2022-03-012023-02-2806828498core:LandBuildings2022-03-012023-02-2806828498core:PlantMachinery2022-03-012023-02-2806828498core:Vehicles2022-03-012023-02-2806828498core:FurnitureFittings2022-03-012023-02-2806828498core:OfficeEquipment2022-03-012023-02-2806828498dpl:AdministrativeExpenses2022-03-012023-02-2806828498core:NetGoodwill2022-03-012023-02-2806828498core:IntangibleAssetsOtherThanGoodwill2022-03-012023-02-2806828498dpl:GroupUndertakings2022-03-012023-02-2806828498dpl:ParticipatingInterests2022-03-012023-02-2806828498dpl:GroupUndertakingscore:ListedExchangeTraded2022-03-012023-02-2806828498core:ListedExchangeTraded2022-03-012023-02-2806828498dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-03-012023-02-2806828498core:UnlistedNon-exchangeTraded2022-03-012023-02-2806828498core:NetGoodwill2024-02-2906828498core:IntangibleAssetsOtherThanGoodwill2024-02-2906828498core:LandBuildings2024-02-2906828498core:PlantMachinery2024-02-2906828498core:Vehicles2024-02-2906828498core:FurnitureFittings2024-02-2906828498core:OfficeEquipment2024-02-2906828498core:AfterOneYear2024-02-2906828498core:WithinOneYear2024-02-2906828498core:ListedExchangeTraded2024-02-2906828498core:UnlistedNon-exchangeTraded2024-02-2906828498core:ShareCapital2024-02-2906828498core:SharePremium2024-02-2906828498core:RevaluationReserve2024-02-2906828498core:OtherReservesSubtotal2024-02-2906828498core:RetainedEarningsAccumulatedLosses2024-02-2906828498core:NetGoodwill2023-02-2806828498core:IntangibleAssetsOtherThanGoodwill2023-02-2806828498core:LandBuildings2023-02-2806828498core:PlantMachinery2023-02-2806828498core:Vehicles2023-02-2806828498core:FurnitureFittings2023-02-2806828498core:OfficeEquipment2023-02-2806828498core:AfterOneYear2023-02-2806828498core:WithinOneYear2023-02-2806828498core:ListedExchangeTraded2023-02-2806828498core:UnlistedNon-exchangeTraded2023-02-2806828498core:ShareCapital2023-02-2806828498core:SharePremium2023-02-2806828498core:RevaluationReserve2023-02-2806828498core:OtherReservesSubtotal2023-02-2806828498core:RetainedEarningsAccumulatedLosses2023-02-2806828498core:NetGoodwill2022-03-0106828498core:IntangibleAssetsOtherThanGoodwill2022-03-0106828498core:LandBuildings2022-03-0106828498core:PlantMachinery2022-03-0106828498core:Vehicles2022-03-0106828498core:FurnitureFittings2022-03-0106828498core:OfficeEquipment2022-03-0106828498core:AfterOneYear2022-03-0106828498core:WithinOneYear2022-03-0106828498core:ListedExchangeTraded2022-03-0106828498core:UnlistedNon-exchangeTraded2022-03-0106828498core:ShareCapital2022-03-0106828498core:SharePremium2022-03-0106828498core:RevaluationReserve2022-03-0106828498core:OtherReservesSubtotal2022-03-0106828498core:RetainedEarningsAccumulatedLosses2022-03-0106828498core:AfterOneYear2023-03-012024-02-2906828498core:WithinOneYear2023-03-012024-02-2906828498core:Non-currentFinancialInstrumentscore:CostValuation2023-03-012024-02-2906828498core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-012024-02-2906828498core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-012024-02-2906828498core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-012024-02-2906828498core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-012024-02-2906828498core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-012024-02-2906828498core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-012024-02-2906828498core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-012024-02-2906828498core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-012024-02-2906828498core:Non-currentFinancialInstrumentscore:CostValuation2024-02-2906828498core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-02-2906828498core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-02-2906828498core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-02-2906828498core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-02-2906828498core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-02-2906828498core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-02-2906828498core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-02-2906828498core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-02-2906828498core:Non-currentFinancialInstrumentscore:CostValuation2023-02-2806828498core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-02-2806828498core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-02-2806828498core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-02-2806828498core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-02-2806828498core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-02-2806828498core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-02-2806828498core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-02-2806828498core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-02-2806828498bus:Director12023-03-012024-02-2906828498bus:Director22023-03-012024-02-2906828498core:FurnitureFittingsToolsEquipment2023-02-2806828498core:FurnitureFittingsToolsEquipment2023-03-012024-02-2906828498core:FurnitureFittingsToolsEquipment2024-02-29

TOTALLY PHARMACY LTD

Registered Number
06828498
(England and Wales)

Unaudited Financial Statements for the Year ended
29 February 2024

TOTALLY PHARMACY LTD
Company Information
for the year from 1 March 2023 to 29 February 2024

Directors

SAUNDH, Kamaljeet Singh
SAUNDH, Rajpal Kaur

Registered Address

2nd Floor Grove House
55 Lowlands Road
Harrow
HA1 3AW

Registered Number

06828498 (England and Wales)
TOTALLY PHARMACY LTD
Balance Sheet as at
29 February 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Intangible assets3229,667240,267
Tangible assets4104,111117,376
Investments5133,333133,333
467,111490,976
Current assets
Stocks622,50022,170
Debtors7815,350752,488
Cash at bank and on hand121,807138,685
959,657913,343
Creditors amounts falling due within one year8(393,621)(429,706)
Net current assets (liabilities)566,036483,637
Total assets less current liabilities1,033,147974,613
Creditors amounts falling due after one year9(19,775)(22,831)
Net assets1,013,372951,782
Capital and reserves
Called up share capital160,451160,451
Profit and loss account852,921791,331
Shareholders' funds1,013,372951,782
The financial statements were approved and authorised for issue by the Board of Directors on 28 November 2024, and are signed on its behalf by:
SAUNDH, Kamaljeet Singh
Director
Registered Company No. 06828498
TOTALLY PHARMACY LTD
Notes to the Financial Statements
for the year ended 29 February 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. Goodwill is being amortised evenly over its estimated useful life of 25 years.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Plant and machinery25
Fixtures and fittings25
Vehicles25
Office Equipment25
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
Stocks and work in progress
Inventories are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
2.Average number of employees

20242023
Average number of employees during the year810
3.Intangible assets

Goodwill

Other

Total

£££
Cost or valuation
At 01 March 23265,00076,705341,705
At 29 February 24265,00076,705341,705
Amortisation and impairment
At 01 March 2324,73376,705101,438
Charge for year10,600-10,600
At 29 February 2435,33376,705112,038
Net book value
At 29 February 24229,667-229,667
At 28 February 23240,267-240,267
4.Tangible fixed assets

Land & buildings

Plant & machinery

Vehicles

Fixtures & fittings

Office Equipment

Total

££££££
Cost or valuation
At 01 March 23-80,14383,77445,07411,807220,798
Additions4,200--10,2223,55817,980
At 29 February 244,20080,14383,77455,29615,365238,778
Depreciation and impairment
At 01 March 23-12,33847,67635,5087,900103,422
Charge for year-16,9519,0243,9961,27431,245
At 29 February 24-29,28956,70039,5049,174134,667
Net book value
At 29 February 244,20050,85427,07415,7926,191104,111
At 28 February 23-67,80536,0989,5663,907117,376
5.Fixed asset investments

Other investments1

Total

££
Cost or valuation
At 01 March 23133,333133,333
At 29 February 24133,333133,333
Net book value
At 29 February 24133,333133,333
At 28 February 23133,333133,333

Notes

1Other investments other than loans
6.Stocks

2024

2023

££
Finished goods22,50022,170
Total22,50022,170
7.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables191,531307,676
Amounts owed by group undertakings448,543434,318
Other debtors165,6307,626
Prepayments and accrued income9,6462,868
Total815,350752,488
8.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables133,709130,885
Bank borrowings and overdrafts4,9784,396
Taxation and social security28,58124,584
Payments received on account66,05683,618
Other creditors112,795153,550
Accrued liabilities and deferred income47,50232,673
Total393,621429,706
9.Creditors: amounts due after one year

2024

2023

££
Bank borrowings and overdrafts19,77522,831
Total19,77522,831
10.Related party transactions
At the yearend, Totally Investments Ltd owed £448,543 (2023: £434,318) to Totally Pharmacy Ltd. The companies are related as Kamaljeet Saundh and Rajpal Saundh are the directors in both companies.